Kyma Medical Technologies

Kyma Medical Technologies, established in 2008, was a medical device company focused on developing remote patient monitoring solutions for individuals with chronic cardiac illnesses. The company was founded by engineers Assaf Bernstein and Uriel Weinstein, who had previously worked together at the biomedical company QuantomiX. The firm's operations were based in Kfar Saba, Israel, with additional offices in California.

Kyma Medical's core product was the µ-Cor System, a non-invasive, wearable device designed to monitor the early signs of congestive heart failure. This system utilizes a proprietary radio frequency (RF) technology to track fluid levels in the lungs, a critical indicator for heart failure patients. Beyond thoracic fluid content, the µ-Cor patch continuously records multiple vital signs, including electrocardiogram (ECG), heart rate, respiration rate, activity levels, and posture. The collected data is transmitted wirelessly from the wearable sensor to a gateway device and then to a remote service center for analysis by certified technicians. Proprietary algorithms analyze this data to identify patient-specific trends, and if a potential deterioration in the patient's condition is detected, the system automatically notifies the patient's medical team. This approach facilitates early intervention, aiming to reduce hospital readmissions and improve patient outcomes.

A significant milestone for the company was receiving the CE Mark approval in Europe in January 2015, which certified the µ-Cor System for monitoring thoracic fluid, ECG, and other vital signs. The company's business model centered on the sale of these sophisticated medical devices and the associated data analysis services to healthcare professionals and institutions. In October 2013, Kyma secured $10 million in a Series A funding round from investors including Elron Electronic Industries, Rafael Development Corporation, and Ganot Capital. This investment supported the continued development and commercialization of its technology. In September 2015, Kyma Medical Technologies was acquired by ZOLL Medical Corporation, a U.S.-based manufacturer of medical devices, for an upfront payment of $35 million, with additional milestone payments. The acquisition integrated Kyma into ZOLL's LifeVest division, leveraging ZOLL's global network to broaden the market reach of the µ-Cor technology.

Keywords: remote patient monitoring, chronic heart failure, congestive heart failure, medical device, thoracic fluid monitoring, RF sensing technology, wearable sensor, ECG monitoring, vital signs tracking, cardiac care, telehealth, non-invasive monitoring, patient data analysis, medical algorithms, CE Mark, ZOLL Medical, heart rate monitoring, respiration rate, activity tracking, digital health